Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL495 in advanced solid tumors
NCT06630247Phase 1Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of XL495 in solid tumor and urothelial carcinoma (UC) (3 arms), sponsored by Exelixis, Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 18 months, Dose-limiting Toxicities up to 18 months and 1 more. Started Oct 2024; status: terminated.
02
Drugs
XL495
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06630247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630247.